HUTCHMED: Fruquintinib Phase III Met Primary Endpoint in Metastatic Colorectal Cancer

 — Trial met primary endpoint of overall survival and all secondary endpoints —

— Overall safety consistent with fruquintinib known profile —

— Plans for regulatory submissions underway in the U.S., Europe and Japan —

— Results to be submitted to an upcoming medical meeting —

https://www.globenewswire.com/news-release/2022/08/08/2493507/0/en/HUTCHMED-Announces-that-Fruquintinib-Global-Phase-III-FRESCO-2-Study-Has-Met-Its-Primary-Endpoint-in-Metastatic-Colorectal-Cancer.html